transcatheter mitral valve

Resultados alentadores en la válvula mitral percutánea en los pacientes complejos

Transcatheter Mitral Valve Replacement vs. Medical Therapy

Mitral valve regurgitation (MR) is a common cause behind heart failure and is associated to hospitalization for heart failure and higher mortality.&nbsp; Transcatheter edge-to-edge repair (TEER), together with guideline-directed medical therapy (GDMT) has been shown beneficial in high risk patients, according to the COAPT study. However, there is a significant group of patients that make<a href="https://solaci.org/en/2023/07/04/transcatheter-mitral-valve-replacement-vs-medical-therapy/" title="Read more" >...</a>

Mejoras tecnológicas en las válvulas que se traducen en resultados clínicos

Transcatheter Mitral Valve Replacement Devices Multiply

The Transcatheter mitral valve replacement&nbsp;has been established as gold standard for patients with intermediate or high risk severe aortic stenosis. The supporting evidence was initially gathered with one or two safe and effective devices that worked really well, so that later on prosthetic valves multiplied, for competing companies wanted their share of the market. However,<a href="https://solaci.org/en/2018/02/12/transcatheter-mitral-valve-replacement-devices-multiply/" title="Read more" >...</a>

reemplazo valvular mitral por cateter en insuficiencia mitral sintomática

Transcatheter Mitral Valve Replacement for Severe Mitral Regurgitation: A Global Study

Symptomatic mitral regurgitation is associated with high morbidity and mortality that can be alleviated partly by surgical mitral valve replacement. However, many patients do not undergo surgery. Transcatheter mitral valve replacement is an appealing option for this selected patient group. &nbsp; This study aimed to examine the effectiveness and safety of transcatheter mitral valve replacement<a href="https://solaci.org/en/2017/01/27/transcatheter-mitral-valve-replacement-for-severe-mitral-regurgitation-a-global-study/" title="Read more" >...</a>

Transcatheter Mitral Valve Replacement

Transcatheter Mitral Valve Replacement: A New Arrow in the Bow

Original Title: Transcatheter Mitral Valve Replacement in Native Mitral Valve Disease With Severe Mitral Annular Calcification: Results From the First Multicenter Global Registry Reference: J Am Coll Cardiol Intv. 2016;9(13):1361-1371. doi:10.1016/j.jcin.2016.04.022 Gentileza del Dr. Agustín Vecchia. The risk underlying the surgical approach to mitral valve replacement in patients with severe mitral annular calcification is high. A<a href="https://solaci.org/en/2016/07/15/transcatheter-mitral-valve-replacement-a-new-arrow-in-the-bow/" title="Read more" >...</a>

valvula tricuspide

Cardioband in Tricuspid Valve Regurgitation

Untreated tricuspid regurgitation (TR) has been associated to high morbimortality. Surgical treatment of isolated severe TR is complex and carries a high mortality rate.&nbsp; A transcatheter treatment of this valve is currently being developed, and different concepts are being applied to the new devices.&nbsp; Even though most TR is secondary, atrial functional tricuspid regurgitation (A-FTR)<a href="https://solaci.org/en/2024/07/04/cardioband-in-tricuspid-valve-regurgitation/" title="Read more" >...</a>

Transcatheter Myotomy for the Treatment of the Dynamic Obstruction of the Left Ventricular Outflow Tract

Septal reduction therapies are used to mitigate the symptoms caused by dynamic left ventricular outflow tract (LVOT) obstruction and the associated mitral regurgitation (MR) that can surge in hypertrophic cardiomyopathy (HCM).&nbsp; Alternative therapies to treat LVOT obstruction include surgical procedures, i.e. surgical myotomy or myomectomy, or alcohol and radiofrequency septal ablation (intracardiac, transthoracic and endocardial,<a href="https://solaci.org/en/2024/03/24/transcatheter-myotomy-for-the-treatment-of-the-dynamic-obstruction-of-the-left-ventricular-outflow-tract/" title="Read more" >...</a>

Cierre de orejuela izquierda

Left Atrial Appendage Closure and Concomitant Transcatheter Intervention: Can We?

Several scientific societies support performing left atrial appendage occlusion (LAAO) as a stand-alone procedure, even though it is often associated to other cardiomyopathies requiring transcatheter intervention.&nbsp; Though still controversial, combining LAAO and any other cardiac intervention might reduce hospitalizations, as well as the need for additional punctures, anesthesia, red tape, a longer stay and higher<a href="https://solaci.org/en/2024/02/06/left-atrial-appendage-closure-and-concomitant-transcatheter-intervention-can-we/" title="Read more" >...</a>

valvula tricuspide

TricValve: 12-Month Evolution

Tricuspid regurgitation has become increasingly common, and current pharmacological treatment options are limited. In turn, surgery, which is a complex alternative, carries considerable rates of complications and mortality. In response to this issue, various percutaneous systems are being developed, such as edge-to-edge treatment, percutaneous annuloplasty, and caval valve implantation (CAVI), among others. In the analysis<a href="https://solaci.org/en/2024/01/18/tricvalve-12-month-evolution/" title="Read more" >...</a>

Luz roja para el TAVI en pacientes de bajo riesgo

MYVAL, a TAVR Balloon-Expandable Valve with Promising Results

TAVR has been shown beneficial over time, and with the development of new generation of prosthetic valves and implantation techniques, outcomes have been improved, reducing the incidence of leaks y and the need for definite pacemaker.&nbsp; This study looked at the evolution of 100 patients with symptomatic aortic stenosis treated with Myval THV from Meril<a href="https://solaci.org/en/2023/12/19/myval-a-tavr-balloon-expandable-valve-with-promising-results/" title="Read more" >...</a>

Top